Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Phase 2/3 Completed 514 enrolled Sunshine Lake Pharma Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection

Timeline

Start: 2021-06-21
Primary completion: 2023-04-11
Completion: 2023-04-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HEC110114	Unknown	600 mg	Oral
Subject	HEC74647PA	Unknown	100 mg	Oral
Subject	HEC74647PA	Unknown	200 mg	Oral

Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Summary

Timeline

Drugs

Indications